Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.56
GSK's Cash to Debt is ranked lower than
73% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. GSK: 0.56 )
Ranked among companies with meaningful Cash to Debt only.
GSK' s 10-Year Cash to Debt Range
Min: 0.02  Med: 0.53 Max: N/A
Current: 0.56
Equity to Asset 0.13
GSK's Equity to Asset is ranked lower than
95% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. GSK: 0.13 )
Ranked among companies with meaningful Equity to Asset only.
GSK' s 10-Year Equity to Asset Range
Min: 0.05  Med: 0.25 Max: 0.4
Current: 0.13
0.05
0.4
Interest Coverage 5.23
GSK's Interest Coverage is ranked lower than
86% of the 370 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 933.44 vs. GSK: 5.23 )
Ranked among companies with meaningful Interest Coverage only.
GSK' s 10-Year Interest Coverage Range
Min: 0.81  Med: 11.99 Max: 28.06
Current: 5.23
0.81
28.06
F-Score: 6
Z-Score: 2.03
M-Score: -1.95
WACC vs ROIC
8.52%
53.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 51.04
GSK's Operating margin (%) is ranked higher than
98% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. GSK: 51.04 )
Ranked among companies with meaningful Operating margin (%) only.
GSK' s 10-Year Operating margin (%) Range
Min: 1.68  Med: 28.66 Max: 36.94
Current: 51.04
1.68
36.94
Net-margin (%) 44.22
GSK's Net-margin (%) is ranked higher than
96% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.85 vs. GSK: 44.22 )
Ranked among companies with meaningful Net-margin (%) only.
GSK' s 10-Year Net-margin (%) Range
Min: 5.76  Med: 20.03 Max: 23.94
Current: 44.22
5.76
23.94
ROE (%) 172.64
GSK's ROE (%) is ranked higher than
100% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.87 vs. GSK: 172.64 )
Ranked among companies with meaningful ROE (%) only.
GSK' s 10-Year ROE (%) Range
Min: 17.3  Med: 62.19 Max: 244.21
Current: 172.64
17.3
244.21
ROA (%) 23.39
GSK's ROA (%) is ranked higher than
94% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. GSK: 23.39 )
Ranked among companies with meaningful ROA (%) only.
GSK' s 10-Year ROA (%) Range
Min: 3.84  Med: 17.77 Max: 26.32
Current: 23.39
3.84
26.32
ROC (Joel Greenblatt) (%) 135.04
GSK's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.80 vs. GSK: 135.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GSK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 40.79  Med: 83.56 Max: 148.93
Current: 135.04
40.79
148.93
Revenue Growth (3Y)(%) -4.10
GSK's Revenue Growth (3Y)(%) is ranked lower than
77% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. GSK: -4.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GSK' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.1  Med: 4.80 Max: 15.3
Current: -4.1
-4.1
15.3
EBITDA Growth (3Y)(%) -18.40
GSK's EBITDA Growth (3Y)(%) is ranked lower than
79% of the 476 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. GSK: -18.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GSK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -18.4  Med: 7.70 Max: 17.3
Current: -18.4
-18.4
17.3
EPS Growth (3Y)(%) -17.90
GSK's EPS Growth (3Y)(%) is ranked lower than
76% of the 447 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. GSK: -17.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GSK' s 10-Year EPS Growth (3Y)(%) Range
Min: -30.2  Med: 5.40 Max: 51.4
Current: -17.9
-30.2
51.4
» GSK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

GSK Guru Trades in Q2 2014

Pioneer Investments 93,226 sh (New)
James Barrow 270,900 sh (New)
HOTCHKIS & WILEY 4,949,118 sh (+13358.60%)
John Rogers 988,772 sh (+49.33%)
Jim Simons 8,869,400 sh (+26.53%)
Charles Brandes 2,500,048 sh (+15.52%)
Ken Fisher 11,365,903 sh (+1.35%)
Murray Stahl 23,992 sh (+0.84%)
Manning & Napier Advisors, Inc 331,544 sh (+0.76%)
Joel Greenblatt 83,528 sh (+0.09%)
NWQ Managers 148,850 sh (+0.03%)
First Eagle Investment 1 sh (unchged)
Francis Chou 18,000 sh (unchged)
John Hussman 323,500 sh (unchged)
Louis Moore Bacon Sold Out
Dodge & Cox 60,226,050 sh (-0.27%)
Tweedy Browne 142,118 sh (-0.34%)
Jeff Auxier 108,620 sh (-0.50%)
Diamond Hill Capital 189,641 sh (-0.70%)
Bill Frels 3,846 sh (-14.46%)
PRIMECAP Management 5,156,449 sh (-43.82%)
» More
Q3 2014

GSK Guru Trades in Q3 2014

David Dreman 1,328 sh (New)
Kahn Brothers 51,000 sh (New)
HOTCHKIS & WILEY 10,804,564 sh (+118.31%)
NWQ Managers 208,125 sh (+39.82%)
Charles Brandes 3,415,717 sh (+36.63%)
Jeff Auxier 133,518 sh (+22.92%)
John Rogers 1,005,634 sh (+1.71%)
Ken Fisher 11,488,594 sh (+1.08%)
Manning & Napier Advisors, Inc 333,460 sh (+0.58%)
Murray Stahl 24,022 sh (+0.13%)
Francis Chou 18,000 sh (unchged)
Louis Moore Bacon 300,000 sh (unchged)
Pioneer Investments 331,758 sh (unchged)
First Eagle Investment 1 sh (unchged)
James Barrow 270,900 sh (unchged)
John Hussman 323,500 sh (unchged)
Bill Frels Sold Out
Joel Greenblatt 83,462 sh (-0.08%)
Tweedy Browne 140,278 sh (-1.29%)
PRIMECAP Management 4,874,635 sh (-5.47%)
Jim Simons 6,827,600 sh (-23.02%)
Dodge & Cox 38,589,161 sh (-35.93%)
Diamond Hill Capital 14,902 sh (-92.14%)
» More
Q4 2014

GSK Guru Trades in Q4 2014

Pioneer Investments 1,206,201 sh (+263.58%)
Diamond Hill Capital 54,042 sh (+262.65%)
HOTCHKIS & WILEY 12,213,885 sh (+13.04%)
Manning & Napier Advisors, Inc 356,579 sh (+6.93%)
John Rogers 1,044,923 sh (+3.91%)
Jeff Auxier 138,693 sh (+3.88%)
Kahn Brothers 51,000 sh (unchged)
First Eagle Investment 1 sh (unchged)
Louis Moore Bacon 500,000 sh (unchged)
Francis Chou 18,000 sh (unchged)
James Barrow 270,900 sh (unchged)
David Dreman Sold Out
PRIMECAP Management 4,873,235 sh (-0.03%)
Joel Greenblatt 83,233 sh (-0.27%)
Murray Stahl 23,723 sh (-1.24%)
NWQ Managers 204,625 sh (-1.68%)
Charles Brandes 3,281,780 sh (-3.92%)
Tweedy Browne 134,293 sh (-4.27%)
Ken Fisher 10,765,004 sh (-6.30%)
John Hussman 300,000 sh (-7.26%)
Jim Simons 6,006,800 sh (-12.02%)
Dodge & Cox 23,959,301 sh (-37.91%)
» More
Q1 2015

GSK Guru Trades in Q1 2015

Sarah Ketterer 439,614 sh (New)
NWQ Managers 456,380 sh (+123.03%)
Diamond Hill Capital 93,778 sh (+73.53%)
Charles Brandes 3,879,073 sh (+18.20%)
Kahn Brothers 58,200 sh (+14.12%)
HOTCHKIS & WILEY 12,302,975 sh (+0.73%)
Joel Greenblatt 83,578 sh (+0.41%)
Pioneer Investments 1,208,920 sh (+0.23%)
Murray Stahl 23,773 sh (+0.21%)
First Eagle Investment 1 sh (unchged)
John Rogers 1,044,933 sh (unchged)
James Barrow 270,900 sh (unchged)
Francis Chou 18,000 sh (unchged)
John Hussman Sold Out
Ken Fisher 10,757,080 sh (-0.07%)
Manning & Napier Advisors, Inc 349,605 sh (-1.96%)
Dodge & Cox 23,436,551 sh (-2.18%)
Tweedy Browne 131,346 sh (-2.19%)
PRIMECAP Management 4,597,935 sh (-5.65%)
Jeff Auxier 71,417 sh (-48.51%)
Jim Simons 2,612,600 sh (-56.51%)
» More
» Details

Insider Trades

Latest Guru Trades with GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on GlaxoSmithKline PLC

Diamond Hill Capital Comments on GlaxoSmithKline PLC - Oct 17, 2014

We eliminated our position in GlaxoSmithKline PLC (GSK) due to concerns that the company will not be able to preserve the recent level of revenue or profitability generated by its respiratory franchise. Despite its development of high efficacy next generation respiratory drugs that have come to market in advance of Advair losing patent protection, the company is facing extreme pricing pressure from health care payors. Diversified machinery manufacturer Dover Corp. was eliminated as the stock price approached our estimate of intrinsic value.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on GlaxoSmithKline PLC - Jun 26, 2014

Global pharmaceutical company GlaxoSmithKline PLC (GSK) has several attractive franchises and pipeline drug candidates that have the potential to add significant value.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about GlaxoSmithKline PLC

Irving Kahn Buys Stake in GlaxoSmithKline During Q3 2014
During the third quarter, Irving Kahn (Trades, Portfolio) of Kahn Brothers added only one position to the portfolio, and increased his holdings in just two companies. The majority of his activity was reducing his positions in 13 companies. Read more...
Diamond Hill Capital Comments on GlaxoSmithKline PLC
We eliminated our position in GlaxoSmithKline PLC (GSK) due to concerns that the company will not be able to preserve the recent level of revenue or profitability generated by its respiratory franchise. Despite its development of high efficacy next generation respiratory drugs that have come to market in advance of Advair losing patent protection, the company is facing extreme pricing pressure from health care payors. Diversified machinery manufacturer Dover Corp. was eliminated as the stock price approached our estimate of intrinsic value. Read more...
Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG
According to GuruFocus list of 52-week lows, these Guru stocks have reached their 52-week lows. Read more...
A Look at the Week's Top Dividend Growers
During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 6.39
GSK's P/E(ttm) is ranked higher than
96% of the 469 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.80 vs. GSK: 6.39 )
Ranked among companies with meaningful P/E(ttm) only.
GSK' s 10-Year P/E(ttm) Range
Min: 6.39  Med: 15.17 Max: 40.41
Current: 6.39
6.39
40.41
Forward P/E 17.27
GSK's Forward P/E is ranked higher than
66% of the 244 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.58 vs. GSK: 17.27 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 6.60
GSK's PE(NRI) is ranked higher than
96% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.50 vs. GSK: 6.60 )
Ranked among companies with meaningful PE(NRI) only.
GSK' s 10-Year PE(NRI) Range
Min: 6.52  Med: 15.20 Max: 41.19
Current: 6.6
6.52
41.19
P/B 8.70
GSK's P/B is ranked lower than
82% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. GSK: 8.70 )
Ranked among companies with meaningful P/B only.
GSK' s 10-Year P/B Range
Min: 5.48  Med: 9.20 Max: 19.41
Current: 8.7
5.48
19.41
P/S 2.82
GSK's P/S is ranked higher than
57% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. GSK: 2.82 )
Ranked among companies with meaningful P/S only.
GSK' s 10-Year P/S Range
Min: 1.94  Med: 2.90 Max: 4.9
Current: 2.82
1.94
4.9
PFCF 22.72
GSK's PFCF is ranked higher than
73% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.65 vs. GSK: 22.72 )
Ranked among companies with meaningful PFCF only.
GSK' s 10-Year PFCF Range
Min: 8.21  Med: 16.65 Max: 41.33
Current: 22.72
8.21
41.33
POCF 13.96
GSK's POCF is ranked higher than
80% of the 399 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.21 vs. GSK: 13.96 )
Ranked among companies with meaningful POCF only.
GSK' s 10-Year POCF Range
Min: 6.64  Med: 12.23 Max: 20.67
Current: 13.96
6.64
20.67
EV-to-EBIT 6.17
GSK's EV-to-EBIT is ranked higher than
95% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.91 vs. GSK: 6.17 )
Ranked among companies with meaningful EV-to-EBIT only.
GSK' s 10-Year EV-to-EBIT Range
Min: 6.6  Med: 12.00 Max: 240.2
Current: 6.17
6.6
240.2
Shiller P/E 12.06
GSK's Shiller P/E is ranked higher than
88% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.23 vs. GSK: 12.06 )
Ranked among companies with meaningful Shiller P/E only.
GSK' s 10-Year Shiller P/E Range
Min: 10.82  Med: 15.53 Max: 21.15
Current: 12.06
10.82
21.15
Current Ratio 1.32
GSK's Current Ratio is ranked lower than
78% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. GSK: 1.32 )
Ranked among companies with meaningful Current Ratio only.
GSK' s 10-Year Current Ratio Range
Min: 0.97  Med: 1.27 Max: 1.78
Current: 1.32
0.97
1.78
Quick Ratio 1.03
GSK's Quick Ratio is ranked lower than
74% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. GSK: 1.03 )
Ranked among companies with meaningful Quick Ratio only.
GSK' s 10-Year Quick Ratio Range
Min: 0.68  Med: 1.01 Max: 1.42
Current: 1.03
0.68
1.42
Days Inventory 202.26
GSK's Days Inventory is ranked lower than
83% of the 616 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.37 vs. GSK: 202.26 )
Ranked among companies with meaningful Days Inventory only.
GSK' s 10-Year Days Inventory Range
Min: 145.16  Med: 181.30 Max: 321.53
Current: 202.26
145.16
321.53
Days Sales Outstanding 89.00
GSK's Days Sales Outstanding is ranked lower than
61% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.51 vs. GSK: 89.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
GSK' s 10-Year Days Sales Outstanding Range
Min: 54.62  Med: 74.40 Max: 114.48
Current: 89
54.62
114.48

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 6.02
GSK's Dividend Yield is ranked higher than
97% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. GSK: 6.02 )
Ranked among companies with meaningful Dividend Yield only.
GSK' s 10-Year Dividend Yield Range
Min: 2.72  Med: 4.92 Max: 6.07
Current: 6.02
2.72
6.07
Dividend Payout 0.38
GSK's Dividend Payout is ranked higher than
99% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. GSK: 0.38 )
Ranked among companies with meaningful Dividend Payout only.
GSK' s 10-Year Dividend Payout Range
Min: 0.14  Med: 0.68 Max: 4.69
Current: 0.38
0.14
4.69
Dividend growth (3y) 1.90
GSK's Dividend growth (3y) is ranked lower than
64% of the 246 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. GSK: 1.90 )
Ranked among companies with meaningful Dividend growth (3y) only.
GSK' s 10-Year Dividend growth (3y) Range
Min: -12.6  Med: 7.70 Max: 20.8
Current: 1.9
-12.6
20.8
Yield on cost (5-Year) 8.33
GSK's Yield on cost (5-Year) is ranked higher than
96% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. GSK: 8.33 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GSK' s 10-Year Yield on cost (5-Year) Range
Min: 3.76  Med: 6.80 Max: 8.39
Current: 8.33
3.76
8.39
Share Buyback Rate 1.60
GSK's Share Buyback Rate is ranked higher than
89% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.40 vs. GSK: 1.60 )
Ranked among companies with meaningful Share Buyback Rate only.
GSK' s 10-Year Share Buyback Rate Range
Min: 3.6  Med: 1.00 Max: -20
Current: 1.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.37
GSK's Price/Projected FCF is ranked higher than
79% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. GSK: 1.37 )
Ranked among companies with meaningful Price/Projected FCF only.
GSK' s 10-Year Price/Projected FCF Range
Min: 0.82  Med: 1.54 Max: 7.52
Current: 1.37
0.82
7.52
Price/Median PS Value 0.97
GSK's Price/Median PS Value is ranked higher than
76% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. GSK: 0.97 )
Ranked among companies with meaningful Price/Median PS Value only.
GSK' s 10-Year Price/Median PS Value Range
Min: 0.69  Med: 1.05 Max: 2.59
Current: 0.97
0.69
2.59
Earnings Yield (Greenblatt) (%) 16.49
GSK's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. GSK: 16.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GSK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.4  Med: 8.40 Max: 16.49
Current: 16.49
0.4
16.49
Forward Rate of Return (Yacktman) (%) 10.55
GSK's Forward Rate of Return (Yacktman) (%) is ranked higher than
59% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. GSK: 10.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GSK' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 4  Med: 14.00 Max: 50.3
Current: 10.55
4
50.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GLAXF.USA, GS7.Germany, GSK.Argentina, GSK N.Mexico, GSK.Switzerland, GS7A.Germany,
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatric and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. Its products main categories are: Oral care, Nutritional, Total wellness, and Skin health. Its barands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.
» More Articles for GSK

Headlines

Articles On GuruFocus.com
JW1 Jun 29 2015 
JW1 Jun 28 2015 
JW1 Jun 28 2015 
JW1 Jun 28 2015 
Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK Jun 15 2015 
Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK Jun 14 2015 
Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
Hotchkis & Wiley Large Cap Value Fund Q1 2015 Commentary May 22 2015 
Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer May 22 2015 
9 International Dividend Dogs With Upside Potential May 22 2015 

More From Other Websites
Dow 30 Stock Roundup: Nike Beats Estimates, Verizon Closes AOL Buy - Analyst Blog Jun 26 2015
GlaxoSmithKline upgraded by Liberum Jun 26 2015
Glaxo, Pfizer Meningitis B Vaccines Get ACIP's Category B - Analyst Blog Jun 25 2015
U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group... Jun 24 2015
Why Ashmore Group plc, GlaxoSmithKline plc, Keller Group plc & GKN plc Look Set To Charge Higher! Jun 24 2015
Pfizer to Buy Two Meningitis Vaccines from Glaxo for $130M - Analyst Blog Jun 23 2015
GSK Vaccinates Pfizer to Gain Novartis - Video Blog Jun 23 2015
4 Reasons Why GlaxoSmithKline plc Is One Of The Best Dividend Stocks That Money Can Buy! Jun 23 2015
Pfizer to buy two vaccines from Glaxo Jun 22 2015
GSK sells two meningitis drugs to Pfizer for £82m Jun 22 2015
3 Shares Analysts Hate: GlaxoSmithKline plc, Standard Chartered PLC And Anglo American plc Jun 22 2015
GlaxoSmithKline (GSK) Stock Gains Following Meningitis Vaccines Sale to Pfizer Jun 22 2015
Pfizer to Acquire Two Meningitis Vaccines Jun 22 2015
GSK sells two vaccines to Pfizer to ease competition concerns Jun 22 2015
GSK sells two vaccines to Pfizer to ease competition concerns Jun 22 2015
Regulatory update on divestment of Nimenrix and Mencevax Jun 22 2015
How GlaxoSmithKline plc Gave Away $2bn! Jun 19 2015
British Investigator Says Chinese Officials Tried to Force Confession Jun 18 2015
Chardan: Sell Axovant Sciences, RVT-101 Market Pricing Is 'Highly Irrational' Jun 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK